- Home
- RAPP
as 11-18-2025 3:37pm EST
Stocks
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.2B | IPO Year: | 2024 |
| Target Price: | $46.50 | AVG Volume (30 days): | 359.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.43 - $42.27 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Rapport Therapeutics Inc. Common Stock (RAPP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bredt David | RAPP | Chief Scientific Officer | Nov 17 '25 | Sell | $25.12 | 8,500 | $214,090.64 | 406,486 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Nov 17 '25 | Sell | $25.18 | 10,916 | $275,046.92 | 35,978 | |
| Bredt David | RAPP | Chief Scientific Officer | Oct 15 '25 | Sell | $25.95 | 8,500 | $219,196.21 | 406,486 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Oct 15 '25 | Sell | $25.95 | 10,916 | $281,729.14 | 35,978 | |
| Ceesay Abraham | RAPP | Chief Executive Officer | Sep 17 '25 | Sell | $26.63 | 76,420 | $2,011,197.18 | 35,978 | |
| Bredt David | RAPP | Chief Scientific Officer | Sep 15 '25 | Sell | $24.27 | 8,500 | $205,648.68 | 406,486 | |
| Huber Reid M | RAPP | Director | Sep 12 '25 | Buy | $24.48 | 20,400 | $499,373.64 | 20,400 | |
| PAUL STEVEN M | RAPP | Director | Sep 12 '25 | Buy | $24.74 | 41,666 | $1,027,111.28 | 28,284 | |
| Young Wendy B. | RAPP | Director | Sep 11 '25 | Buy | $22.60 | 3,500 | $79,100.00 | 9,500 | |
| Gault Cheryl | RAPP | Chief Operating Officer | Sep 8 '25 | Sell | $38.33 | 5,000 | $191,650.00 | 171,928 |
Latest Rapport Therapeutics Inc. Common Stock News
RAPP Breaking Stock News: Dive into RAPP Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 months ago
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
GlobeNewswire
6 months ago
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
6 months ago
Rapport Therapeutics to Host 2025 Investor and Analyst Day
Simply Wall St.
6 months ago
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth
GlobeNewswire
6 months ago
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
GlobeNewswire
7 months ago
Rapport Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
8 months ago
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
Simply Wall St.
8 months ago
Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock
Compare RAPP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPP Rapport Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.